Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Pathologic Complete Response 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1

Interventions

Cyclophosphamide 13fludarabine 11Mycophenolic Acid 9Busulfan 8fludarabine phosphate 7Tacrolimus 7pirtobrutinib 6Whole-Body Irradiation 6Rituximab 6Melphalan 6Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4venetoclax 3nilotinib 3lintuzumab 3Stem Cell Transplantation 3Sirolimus 3Platelet Transfusion 3Methotrexate 3Cytarabine 3Cyclosporine 3Alemtuzumab 3vosaroxin 2ruxolitinib 2ibrutinib 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cc-486 × Other hematologic neoplasm × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡